Immune Memory After Papillomavirus Vaccination (IMAP-I) Study.
Phase of Trial: Phase IV
Latest Information Update: 11 Sep 2016
At a glance
- Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
- Indications Cervical cancer; Human papillomavirus infections
- Focus Biomarker; Pharmacodynamics
- Acronyms IMAP-1
- 09 Apr 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 09 Apr 2012 Planned end date changed from 1 Jan 2016 to 1 Apr 2016 as reported by ClinicalTrials.gov.
- 10 Jan 2012 New trial record